Shiny Brands Group (6703) reported revenue of NT$334.4 million for Oct 2026, +12.3% year on year and +19.0% from the previous month. Revenue for Jan–Oct 2026 was NT$2.87 billion (+15.5% year on year).
Year-on-year revenue growth: 13 months in a row. →
In Oct 2026, it ranked No. 30 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$334.4 million | +12.3% | +19.0% |
| Sep 2026 | NT$280.9 million | +35.9% | +3.6% |
| Aug 2026 | NT$271.2 million | +1.8% | +2.6% |
| Jul 2026 | NT$264.2 million | +32.5% | -16.4% |
| Jun 2026 | NT$316.2 million | +13.6% | +2.7% |
| May 2026 | NT$307.8 million | +16.8% | -11.4% |
| Apr 2026 | NT$347.5 million | +20.3% | +12.7% |
| Mar 2026 | NT$308.4 million | +11.3% | +56.0% |
| Feb 2026 | NT$197.7 million | +5.5% | -17.1% |
| Jan 2026 | NT$238.4 million | +10.4% | -12.4% |
| Dec 2025 | NT$272.1 million | +28.4% | -49.0% |
| Nov 2025 | NT$533.6 million | +3.9% | +79.3% |
| Oct 2025 | NT$297.6 million | +8.9% | +44.0% |
| Sep 2025 | NT$206.7 million | -21.2% | -22.4% |
| Aug 2025 | NT$266.3 million | -5.7% | +33.5% |
| Jul 2025 | NT$199.4 million | -17.1% | -28.3% |
| Jun 2025 | NT$278.2 million | -7.7% | +5.6% |
| May 2025 | NT$263.5 million | -27.2% | -8.8% |
| Apr 2025 | NT$288.9 million | -12.9% | +4.3% |
| Mar 2025 | NT$277 million | -13.2% | +47.9% |
| Feb 2025 | NT$187.3 million | -12.5% | -13.2% |
| Jan 2025 | NT$215.9 million | -20.3% | +1.9% |
| Dec 2024 | NT$212 million | -11.7% | -58.7% |
| Nov 2024 | NT$513.5 million | +0.6% | +87.8% |
| Oct 2024 | NT$273.4 million | -2.1% | +4.2% |
Jan–Oct 2026 cumulative: NT$2.87 billion (+15.5% YoY)
Other Biotech & Medical companies
Compare with peers: Shiny Brands Group vs PEC / Shiny Brands Group vs Lotus Pharm / Shiny Brands Group vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16